ArticlePloS one2026
Graph former-CL: A novel graph transformer with contrastive learning framework for enhanced drug-drug interaction prediction.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-drug interactions (DDI) represent a significant clinical challenge in modern healthcare, contributing to over 125,000 deaths annually in the United States alone. Current computational approaches face substantial limitations in capturing long-range molecular dependencies and generalizing to novel drug combinations. Traditional Graph Neural Networks (GNNs) suffer from over-smoothing and locality bias, while sequence-based methods fail to adequately represent three-dimensional molecular structures. To address these limitations, we propose Graph Former-CL, a novel deep learning framework that synergistically combines Graph Transformer architecture with contrastive learning for DDI prediction. Our approach features four key innovations: (1) a hierarchical Graph Transformer with position-aware multi- head self-attention to capture both local and global molecular patterns, (2) a domain-specific contrastive learning module with molecular augmentation strategies, (3) a cross-modal fusion mechanism integrating SMILES sequences with graph representations, and (4) an adaptive pooling strategy for multi-scale molecular representation. Comprehensive evaluation on four benchmark datasets demonstrates superior performance, with Graph Former-CL achieving 98.2% accuracy on DrugBank and 89.4% on TWOSIDES, both representing statistically significant improvements (p < 0.001) over state-of-the-art methods. Notably, the framework achieves 85.6% accuracy for novel drugs in inductive settings, demonstrating robust generalization capabilities essential for real-world clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.